RxDoctor Payments Data

Linda Allibalogun

Psychiatric/Mental Health · Owings Mills, MDNPI 1255689717

Payments from drug & device makers

$1,218in general payments, 2019–2025

Across 26 payments — averaging $46.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neuronetics, Inc.$789
  • AbbVie$225
  • Takeda Pharmaceuticals U.S.A., Inc.$54
  • Axsome Therapeutics, Inc.$48
  • Tris Pharma Inc$44
  • Supernus Pharmaceuticals, Inc.$35
  • plus $23 from 1 others

What the payments were for

  • Travel & lodging$60249%
  • Food & beverage$61651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,218 in reported general payments places this provider in the 75th percentile of 1,461 psychiatric/mental health providers in Maryland.

See all psychiatric/mental health providers in Maryland

Medicare billing

Part B allowed, 2024
$40,310
Medicare patients
29
Services billed
405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl12$16,246
AuvelityDextromethorphan Hbr/Bupropion15$15,484
Lamotrigine ErLamotrigine19$3,690
Duloxetine Hcl35$1,620
Desvenlafaxine Succinate ErDesvenlafaxine Succinate12$1,200
Quetiapine Fumarate19$604
Olanzapine33$599
Naltrexone Hcl15$541
Haloperidol18$366
Buspirone Hcl23$302
Ziprasidone Hcl13$289
Clonazepam31$283
Divalproex Sodium17$245
Trazodone Hcl65$233
Risperidone23$228

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$225$16,24612 claims
Axsome Therapeutics, Inc.Auvelity$48$15,48415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,461 psychiatric/mental health providers in Maryland.

Other psychiatric/mental health in Owings Mills

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →